In this three-part podcast series, hear from seasoned experts from Allucent as they discuss a range of topics, including how small and mid-sized companies can take a more strategic approach to pharmacovigilance, a regulatory & development roadmap for antibody drug conjugates (ADCs) and radionuclide drug conjugates (RDCs), and the use of artificial intelligence in clinical trials and Good Clinical Practice (GCP) compliance.
Check out the podcast episodes below.
⬆- Ep. 2 Advancing Oncology Research: Regulatory & Development Path for ADCs & RDCs
- Ep. 1 Strategic Alliances in the Development and Execution of Pharmacovigilance Strategy
Ep. 2
Advancing Oncology Research: Regulatory & Development Path for ADCs & RDCs
Join us in our second episode of “Partner for Progress: Strategies for Biotech Success”, where we delve into the world of antibody drug conjugates (ADCs) and radionuclide conjugates (RDCs). We’ll explore the tremendous growth potential of these targeted oncology therapies, the challenges faced by small and mid-sized biotech companies, and strategies for navigating the complex regulatory landscape.